CONMED (CNMD)
(Delayed Data from NYSE)
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Zacks News
Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site
by Zacks Equity Research
The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.
Here's Why You Should Hold on to Tandem (TNDM) Stock for Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.
Varian Medical Installs ProBeam at Research Hub in Singapore
by Zacks Equity Research
Varian Medical's (VAR) APAC revenues grow 7% year over year in the fiscal second quarter.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
ResMed (RMD) continues to see strong sales from SaaS business as well as new mask products and devices.
Integra LifeSciences Rides on Product Launch, Faces Rivalry
by Zacks Equity Research
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.
Medtronic to Acquire Titan Spine for Spine Portfolio Boost
by Zacks Equity Research
According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.
ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals
by Zacks Equity Research
ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.
Abbott Rides on Strong CGM, Poor Rhythm Management Ails
by Zacks Equity Research
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
Medtronic's (MDT) EV ICD Pilot Study Results Encourage
by Zacks Equity Research
The study highlights the benefits of traditional, transvenous ICDs offered by the Medtronic's (MDT) EV ICD system.
Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues fall year over year in Q1.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) has been gaining investor confidence on robust performance.
National Vision's (EYE) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.
Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.
LHC Group (LHCG) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
LHC Group (LHCG) gains from solid home health services in Q1, raises 2019 view.
BioScrip's Option Care Merger on Track, Q1 Loss Narrows
by Zacks Equity Research
BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.
Cardinal Health (CAH) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Cardinal Health (CAH) Q3 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, sluggishness in the Medical segment remains a concern.
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.
Wright Medical (WMGI) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Wright Medical (WMGI) Q1 results benefit from higher revenues, solid show by Lower as well as Upper Extremities segments and gross margin expansion. However, rising costs remain a woe.
OPKO Health (OPK) Reports Loss in Q1, Misses Revenue Estimates
by Zacks Equity Research
Lower revenues, weak performing product segment and contraction in gross margin impact OPKO Health's (OPK) Q1 results.
Becton, Dickinson (BDX) Q2 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) gains from BD Medical in fiscal Q2; international revenues down.
Phibro's (PAHC) Q3 Earnings Miss Estimates, Margins Fall
by Zacks Equity Research
Phibro Animal Health (PAHC) sees year-over-year revenue decline in two core segments ??? Animal Health and Mineral Nutrition.
Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up
by Zacks Equity Research
A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results
Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat
by Zacks Equity Research
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.